Status:
COMPLETED
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Attention Deficit Disorder With Hyperactivity
Eligibility:
All Genders
Brief Summary
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
Eligibility Criteria
Inclusion
- Participants have been in the database for greater than or equal to (\>=) 30 days
- Have received, between 1 January, 2013 and 30 September, 2018, a prescription for Concerta, Ritalin, Atomoxetine (ATO) or Guanfacine (GFC)
Exclusion
- \- Participants who received an unspecified Methylphenidate (MPH) formulation
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2020
Estimated Enrollment :
17418 Patients enrolled
Trial Details
Trial ID
NCT04113551
Start Date
October 1 2019
End Date
January 10 2020
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Janssen Investigative Site
Titusville, New Jersey, United States, 08560